Immunohistochemical staining for EBNA2 and IL-18Rα in a series of immunoblastic lymphomas
Patient no. . | Histologic subtype . | Anatomic site . | EBER* . | EBNA2† . | IL-18Rα† . |
|---|---|---|---|---|---|
| 1 | DLBL (I-BL) | Brain | + | — | — |
| 2 | DLBL (IB) | Brain | + | + (70%) | + (50%) |
| 3 | DLBL (IB) | Brain | + | + (70%) | + (20%) |
| 4 | DLBL (IB) | Brain | + | + (65%) | + (60%) |
| 5 | DLBL (IB) | Brain | + | + (70%) | + (10%) |
| 6 | DLBL (IB) | Brain | ND | — | + (65%) |
| 7 | DLBL (IB) | Lymph node | + | — | — |
| 8 | DLBL (IB) | Testis | — | — | — |
| 9 | DLBL (IB) | Skin | — | — | — |
| 10 | DLBL (CB) | Lymph node | — | — | — |
| 11 | DLBL (IB) | Lymph node | — | — | — |
| 12 | DLBL (IB) | Lymph node | + | + (35%) | — |
| 13 | DLBL (IB) | Lymph node | + | — | — |
Patient no. . | Histologic subtype . | Anatomic site . | EBER* . | EBNA2† . | IL-18Rα† . |
|---|---|---|---|---|---|
| 1 | DLBL (I-BL) | Brain | + | — | — |
| 2 | DLBL (IB) | Brain | + | + (70%) | + (50%) |
| 3 | DLBL (IB) | Brain | + | + (70%) | + (20%) |
| 4 | DLBL (IB) | Brain | + | + (65%) | + (60%) |
| 5 | DLBL (IB) | Brain | + | + (70%) | + (10%) |
| 6 | DLBL (IB) | Brain | ND | — | + (65%) |
| 7 | DLBL (IB) | Lymph node | + | — | — |
| 8 | DLBL (IB) | Testis | — | — | — |
| 9 | DLBL (IB) | Skin | — | — | — |
| 10 | DLBL (CB) | Lymph node | — | — | — |
| 11 | DLBL (IB) | Lymph node | — | — | — |
| 12 | DLBL (IB) | Lymph node | + | + (35%) | — |
| 13 | DLBL (IB) | Lymph node | + | — | — |
Results of the immunohistochemical analysis of EBER1, EBNA2, and IL-18Rα.
DLBL indicates diffuse large B-cell lymphoma; I-BL, immunodeficiency-associated Burkitt lymphoma (World Health Organization classification of tumors); IB, immunoblastic variant; ND, not determined; CB, centroblastic variant.
EBER status was determined in a standard in situ hybridization assay.
The percentages of EBNA2-positive or IL-18Rα-positive neoplastic cells are indicated in parentheses.